Literature DB >> 16127044

Genomic approach to identifying the putative target of and mechanisms of resistance to mefloquine in mycobacteria.

Lia Danelishvili1, Martin Wu, Lowell S Young, Luiz E Bermudez.   

Abstract

The emergence of mycobacterial resistance to multiple antimicrobials emphasizes the need for new compounds. The antimycobacterial activity of mefloquine has been recently described. Mycobacterium avium, Mycobacterium smegmatis, and Mycobacterium tuberculosis are susceptible to mefloquine in vitro, and activity was evidenced in vivo against M. avium. Attempts to obtain resistant mutants by both in vitro and in vivo selection have failed. To identify mycobacterial genes regulated in response to mefloquine, we employed DNA microarray and green fluorescent protein (GFP) promoter library techniques. Following mefloquine treatment, RNA was harvested from M. tuberculosis H37Rv, labeled with 32P, and hybridized against a DNA array. Exposure to 4x MIC resulted in a significant stress response, while exposure to a subinhibitory concentration of mefloquine triggered the expression of genes coding for enzymes involved in fatty acid synthesis, the metabolic pathway, and transport across the membrane and other proteins of unknown function. Evaluation of gene expression using an M. avium GFP promoter library exposed to subinhibitory concentrations of mefloquine revealed more than threefold upregulation of 24 genes. To complement the microarray results, we constructed an M. avium genomic library under the control of a strong sigma-70 (G13) promoter in M. smegmatis. Resistant clones were selected in 32 microg/ml of mefloquine (wild-type M. avium, M. tuberculosis, and M. smegmatis are inhibited by 8 microg/ml), and the M. avium genes associated with M. smegmatis resistant to mefloquine were sequenced. Two groups of genes were identified: one affecting membrane transport and one gene that apparently is involved in regulation of cellular replication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127044      PMCID: PMC1195445          DOI: 10.1128/AAC.49.9.3707-3714.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray.

Authors:  M D De Backer; T Ilyina; X J Ma; S Vandoninck; W H Luyten; H Vanden Bossche
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

Authors:  M A Espinal; A Laszlo; L Simonsen; F Boulahbal; S J Kim; A Reniero; S Hoffner; H L Rieder; N Binkin; C Dye; R Williams; M C Raviglione
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

3.  Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization.

Authors:  M Wilson; J DeRisi; H H Kristensen; P Imboden; S Rane; P O Brown; G K Schoolnik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

4.  Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.

Authors:  L E Bermudez; P Kolonoski; M Wu; P A Aralar; C B Inderlied; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 5.  The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum.

Authors:  Jacques Le Bras; Rémy Durand
Journal:  Fundam Clin Pharmacol       Date:  2003-04       Impact factor: 2.748

6.  FACS-optimized mutants of the green fluorescent protein (GFP).

Authors:  B P Cormack; R H Valdivia; S Falkow
Journal:  Gene       Date:  1996       Impact factor: 3.688

7.  Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.

Authors:  Luiz E Bermudez; Peter Kolonoski; Mary Petrofsky; Martin Wu; Clark B Inderlied; Lowell S Young
Journal:  J Infect Dis       Date:  2003-06-04       Impact factor: 5.226

Review 8.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

9.  Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.

Authors:  Esteban C Nannini; Michael Keating; Peter Binstock; George Samonis; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2002-04       Impact factor: 6.072

Review 10.  Tuberculosis: commentary on a reemergent killer.

Authors:  B R Bloom; C J Murray
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

View more
  10 in total

1.  Reconsidering some approved antimicrobial agents for tuberculosis.

Authors:  Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

2.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.

Authors:  Subramaniam Ananthan; Ellen R Faaleolea; Robert C Goldman; Judith V Hobrath; Cecil D Kwong; Barbara E Laughon; Joseph A Maddry; Alka Mehta; Lynn Rasmussen; Robert C Reynolds; John A Secrist; Nice Shindo; Dustin N Showe; Melinda I Sosa; William J Suling; E Lucile White
Journal:  Tuberculosis (Edinb)       Date:  2009-09-15       Impact factor: 3.131

3.  EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.

Authors:  Luiz E Bermudez; Nima Motamedi; Christopher Chee; Gyulnar Baimukanova; Peter Kolonoski; Clark Inderlied; Priscilla Aralar; Guoqiang Wang; Ly Tam Phan; Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

Review 4.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.

Authors:  Ben Gold; Carl Nathan
Journal:  Microbiol Spectr       Date:  2017-01

5.  Mycobacterium avium genes MAV_5138 and MAV_3679 are transcriptional regulators that play a role in invasion of epithelial cells, in part by their regulation of CipA, a putative surface protein interacting with host cell signaling pathways.

Authors:  Melanie J Harriff; Lia Danelishvili; Martin Wu; Cara Wilder; Michael McNamara; Michael L Kent; Luiz E Bermudez
Journal:  J Bacteriol       Date:  2008-12-05       Impact factor: 3.490

6.  Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients.

Authors:  Anbarasu Deenadayalan; Darragh Heaslip; Adhilakshmi Aavudaiyappan Rajendiran; Banurekha Vaithilingam Velayudham; Sheela Frederick; Hong-Liang Yang; Karen Dobos; John T Belisle; Alamelu Raja
Journal:  Mol Cell Proteomics       Date:  2009-12-22       Impact factor: 5.911

7.  (R*,S*)-(±)-1-(2-{[2,8-Bis(trifluoromethyl)quinolin-4-yl](hydroxy)methyl}piperidin-1-yl)ethanone methanol monosolvate.

Authors:  Raoni S B Gonçalves; Marcus V N de Souza; Solange M S V Wardell; James L Wardell; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-09-30

8.  Novel Organic Salts Based on Mefloquine: Synthesis, Solubility, Permeability, and In Vitro Activity against Mycobacterium tuberculosis.

Authors:  Dário Silva; Márcio V C Lopes; Željko Petrovski; Miguel M Santos; Jussevania P Santos; Sueli F Yamada-Ogatta; Marcelle L F Bispo; Marcus V N de Souza; Ana Rita C Duarte; Maria C S Lourenço; Raoni Schroeder B Gonçalves; Luis C Branco
Journal:  Molecules       Date:  2022-08-13       Impact factor: 4.927

9.  Flux Balance Analysis with Objective Function Defined by Proteomics Data-Metabolism of Mycobacterium tuberculosis Exposed to Mefloquine.

Authors:  Daniel Montezano; Laura Meek; Rashmi Gupta; Luiz E Bermudez; José C M Bermudez
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

10.  Genomic Comparisons Reveal Microevolutionary Differences in Mycobacterium abscessus Subspecies.

Authors:  Joon L Tan; Kee P Ng; Chia S Ong; Yun F Ngeow
Journal:  Front Microbiol       Date:  2017-10-23       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.